Of note, 40% (6/15) of high-grade glioma (HGG; WHO grade III–IV) cell lines presented loss of MTAP expression, contrasting with 0% in low-grade glioma (LGG; WHO grade I–II) cell lines (0/3) (Figure 2A,B). This evidence concerns the gene MTAP and central nervous system cancer.